Clinical Cytology Laboratory, Department of Clinical Analysis and Biomedicine, State University of Maringá, Maringá, Paraná, Brazil.
Arch Gynecol Obstet. 2013 Nov;288(5):1125-30. doi: 10.1007/s00404-013-2872-2. Epub 2013 May 5.
We investigated the frequency of cervical intraepithelial neoplasia (CIN) grade II or worse in low-income Brazilian women with persistent low-grade squamous intraepithelial lesions (LSIL).
A retrospective review of medical records was performed for all patients who underwent a loop electrosurgical excision procedure (LEEP) with "see and treat" strategy for persistent LSIL seen on Papanicolaou (Pap) smears (persisting >12 months in at least two consecutive tests, over a 50-month period. We assessed the colposcopy and histopathology results at the time of the procedure and at follow-up, using Pap and histopathology.
Of 106 women, 48 (45.3 %) had no dysplasia by histopathology, 18 (17.0 %) had CIN I, 29 (27.4 %) had CIN II and 10 (9.4 %) had CIN III. Among the patients with CIN, 38 (66.7 %) performed the follow-up. Of these, only 4 (10.5 %) were classified as follow-up (+), all had CIN I. Women with initial CIN I had 16.7 % (n = 2) recurrences; those with initial CIN II had 5.9 % (n = 1); and those with initial CIN III had 11.1 % (n = 1) (p > 0.05).
A very high proportion of the women with persistent LSIL had CIN II/III on post-LEEP histopathology. Recurrence rates were equal to than those that originally caused the patients to be subjected to LEEP (LSIL). The benefits of the "see and treat" protocol by LEEP for persistent LSIL outweigh the risk of overtreatment, principally in low-resource settings where poor patient compliance is expected, as in Brazil.
我们研究了在巴西低收入妇女中,持续性低级别鳞状上皮内病变(LSIL)患者中,宫颈上皮内瘤变(CIN)Ⅱ级或更高级别病变的发生频率。
对所有接受巴氏涂片(Pap)检查发现持续性 LSIL(至少两次连续检查持续>12 个月,在 50 个月期间)且采用“观察和治疗”策略行环形电切术(LEEP)的患者的病历进行回顾性分析。我们评估了当时的阴道镜检查和组织病理学结果,以及在随访时的 Pap 和组织病理学结果。
在 106 例女性中,48 例(45.3%)组织病理学未见异常,18 例(17.0%)为 CIN I,29 例(27.4%)为 CIN II,10 例(9.4%)为 CIN III。在 CIN 患者中,38 例(66.7%)进行了随访。其中,只有 4 例(10.5%)被归类为随访(+),均为 CIN I。初始 CIN I 的女性中有 16.7%(n=2)复发;初始 CIN II 的女性中有 5.9%(n=1);初始 CIN III 的女性中有 11.1%(n=1)(p>0.05)。
在接受 LEEP 治疗的持续性 LSIL 患者中,CIN II/III 的比例非常高。复发率与最初导致患者接受 LEEP 的病变(LSIL)相同。LEEP 治疗持续性 LSIL 的“观察和治疗”方案的益处大于过度治疗的风险,尤其是在资源匮乏的环境中,患者的依从性较差,就像巴西一样。